# EDGAR Filing Document

**Accession Number:** 0001604191
**File Stem:** 0001437749-25-019912
**Filing Date:** 2025-6
**Character Count:** 15892
**Document Hash:** ef8684fa72e329a40d7988891076f4d7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-019912.hdr.sgml**: 20250609

**ACCESSION NUMBER**: 0001437749-25-019912

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250609

**DATE AS OF CHANGE**: 20250609

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Entero Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001604191
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464993860
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-89966
- **FILM NUMBER:** 251035843

**BUSINESS ADDRESS:**
- **STREET 1:** 777 YAMATO ROAD
- **STREET 2:** SUITE 502
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431
- **BUSINESS PHONE:** 561-589-7020

**MAIL ADDRESS:**
- **STREET 1:** 777 YAMATO ROAD
- **STREET 2:** SUITE 502
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** First Wave BioPharma, Inc.
- **DATE OF NAME CHANGE:** 20210921

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AzurRx BioPharma, Inc.
- **DATE OF NAME CHANGE:** 20141103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioPharma d'Azur, Inc.
- **DATE OF NAME CHANGE:** 20140331
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ali Arif Nasir
- **CENTRAL INDEX KEY:** 0002072056

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** C/O NORTHWEST REGISTERED AGENT
- **STREET 2:** 8735 DUNWOODY PLACE STE N
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30350

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Entero Therapeutics, Inc.**

*(Name of Issuer)*

**Common stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**33749P408**

*(CUSIP Number)*

**Arif Nasir Ali**<br>1841 Chondra Dr<br>Marietta GA 30062<br>404 490 4060

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/02/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **33749P408** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ali Arif Nasir** | Name of reporting person<br>**Ali Arif Nasir** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**250900.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**250900.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**250900.00** | Aggregate amount beneficially owned by each reporting person<br>**250900.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.3%** | Percent of class represented by amount in Row (11)<br>**5.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **33749P408** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Arif Ali IRA Roth** | Name of reporting person<br>**Arif Ali IRA Roth** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**147900.00** | Aggregate amount beneficially owned by each reporting person<br>**147900.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.1%** | Percent of class represented by amount in Row (11)<br>**3.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **33749P408** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ANARP LLC** | Name of reporting person<br>**ANARP LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**WYOMING** | Citizenship or place of organization<br>**WYOMING** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**82800.00** | Aggregate amount beneficially owned by each reporting person<br>**82800.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.7%** | Percent of class represented by amount in Row (11)<br>**1.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **33749P408** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ANANRA LLC TRUST** | Name of reporting person<br>**ANANRA LLC TRUST** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**GEORGIA** | Citizenship or place of organization<br>**GEORGIA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**20200.00** | Aggregate amount beneficially owned by each reporting person<br>**20200.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.4%** | Percent of class represented by amount in Row (11)<br>**0.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common stock, par value $0.0001 per share

**(b) Name of Issuer:**
Entero Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
777 YAMATO ROAD, SUITE 502, BOCA RATON, FL, 33431

This statement on Schedule 13D relates to shares of common stock, $0.0001 par value per share (the "Common Stock"), of Entero Therapeutics, Inc., (the "Issuer"), whose principal executive offices are located at 777 Yamato Road, Suite 502, Boca Raton, Florida.

**Item 4. Purpose of Transaction**

The Reporting Persons purchased the securities reported in this statement for investment purposes. The Reporting Persons do not have any current plans, proposals or negotiations that relate to or would result in any of the matters referred to in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons review their investments on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position, the price levels of the shares of Common Stock, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may, in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, purchasing additional shares of Common Stock, selling shares of Common Stock, engaging in short selling of or any hedging or similar transaction with respect to the Common Stock, taking any other action with respect to the Issuer or any of its securities in any manner permitted by law or changing its intention with respect to any and all matters referred to in paragraphs (a) through (j) of Item 4.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of June 2, 2025, the Reporting Persons beneficially owned in the aggregate 250,900 shares of Common Stock, constituting approximately 5.26% of the outstanding Common Stock. The following sets forth certain information with respect to shares of Common Stock directly beneficially owned by the Reporting Persons:

ANARP LLC beneficially owns 82800 shares of common stock representing 1.74% of the outstanding common stock. Arif Ali IRA Roth beneficially owns 147900 shares of common stock representing 3.10% of the outstanding common stock. ANANRA LLC TRUST beneficially owns 20200 shares of common stock representing 0.42% of the outstanding common stock.

**(b)**
Mr. Ali is the owner of Arif Ali IRA Roth, Manager of ANARP LLC and a Trustee of ANANRA LLC TRUST and, accordingly, may be deemed to be the indirect beneficial owner (as that term is defined under Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) of the Common Stock that Arif Ali IRA Roth, ANARP LLC and ANANRA LLC TRUST own. Mr. Ali has the sole power to vote or direct the vote or to dispose of 250,900 shares of Common Stock. None of Arif Ali IRA Roth, ANARP LLC and ANANRA LLC TRUST have power to vote or direct the vote or to dispose any shares of Common Stock.

Beneficial ownership of the Common Stock shown on the cover pages of and set forth elsewhere in this statement for each of the Reporting Persons assumes that they have not formed a group for purposes of Section 13(d)(3) under the Exchange Act, and Rule 13d-5(b)(1) promulgated thereunder. If the several Reporting Persons were deemed to have formed a group for purposes of Section 13(d)(3) and Rule 13d-5(b)(1), the group would be deemed to own beneficially (and may be deemed to have shared voting and dispositive power over) in the aggregate 250,900 shares of Common Stock, constituting approximately 5.26% of the outstanding shares of Common Stock.

The percentage of shares of Common Stock reported as being beneficially owned is based on 4,765,729 shares of Common Stock outstanding as reported in the 10Q report for quarter ending March 31, 2025 filed on May 15, 2025.

**(c)**
The following sets forth certain information with respect to shares of Common Stock transacted during the past 60 days by the Reporting Persons as listed. Each of the below transactions was effected through the open market:

ANANRA LLC TRUST purchased 28100 shares of common stock on 5/22/2025 at $0.40 per share and sold 7900 shares of common stock on 5/30/2025 at $0.52 per share. Arif Ali IRA Roth purchased 100935 shares of common stock on 05/29/25 at $0.40 per share, sold 100935 shares of common stock on 5/30/2025 at $0.49 per share and purchased 147900 shares of common stock on 6/2/2025 at $0.43 per share. ANARP LLC purchased 82800 shares of common stock on 5/30/2025 at $0.39 per share.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Not Applicable

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ali Arif Nasir

**Signature:** Ali Arif Nasir

**Name/Title:** Individual

**Date:** 06/09/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Arif Ali IRA Roth

**Signature:** Arif Ali IRA Roth

**Name/Title:** Ali Arif Nasir/Owner

**Date:** 06/09/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ANARP LLC

**Signature:** ANARP LLC

**Name/Title:** Ali Arif Nasir/Manager

**Date:** 06/09/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ANANRA LLC TRUST

**Signature:** ANANRA LLC TRUST

**Name/Title:** Ali Arif Nasir/Trustee

**Date:** 06/09/2025